Retrospective Study on the Incidence and Management of Anemia in Oncology

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

349 participants

Study Classification

OBSERVATIONAL

Study Start Date

2020-05-20

Study Completion Date

2021-01-20

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The incidence of anemia ranges from 20 to 75% depending on the type of cancer. It is often present at diagnosis and increases with specific treatments. It has an impact on overall survival and quality of life. Its origins are multiple (pure iron deficiency or functional, malnutrition, dyserythropoiesis, insufficiency renal, hemolysis, chemotherapy, radiotherapy, targeted therapies).

Transfusion is the most common treatment offered in the management of anemia. The incidence of anemia and its consequences are often underestimated during cancer management.

Recommendations were published in 2012. An inventory of the incidence of anemia before and after the publication of these recommendations are proposed in order to assess their impact on daily practice.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Immuno 1: Immune Reconstitution Following Conventional or High-Dose Chemotherapy With Stem Cell Transplant

NCT00231712

Leukemia Medulloblastoma

UNKNOWN

Treatment of Myeloma in Patients <= 65 Years Old With Response >= 50% After HSC Autotransplant by Allogenic Transplant Genoidentical or Phenoidentical After Reduced Intensity Conditioning

NCT00466674

Myeloma

COMPLETED PHASE2

Characteristics and Results of Patients Treated by Therapeutic Intensification

NCT06894381

Malignant Hemopathy

RECRUITING

Hématologie Adulte Prevalence of Adrenal Insufficiency Post-chemotherapy Adrenocorticotropia in Adult Hematology

NCT03688789

Haematological Malignancy

WITHDRAWN NA

Assessment of Elderly Undergoing Allogeneic Hematopoietic Stem Cell Transplantation

NCT04375579

Stem Cell Transplant

ACTIVE_NOT_RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Anemia Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

period 2011

anemia assessment

Intervention Type OTHER

evaluation of anemia status

period 2018

anemia assessment

Intervention Type OTHER

evaluation of anemia status

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

anemia assessment

evaluation of anemia status

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age ≥ 18 years old,
* Follow-up for cancer justifying hospitalization,
* Presenting anemia defined by a hemoglobin level \<11 g / dL,
* Patient not having objected to the collection of his data after oral and written information.

Exclusion Criteria

* patients with a hemoglobin level ≥ 11 g / dL,
* adult patients under guardianship, curatorship or deprived of liberty,
* pregnancy or breast-feeding in progress at the time of hospitalization.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No